Fritextsökning
Innehållstyper
-
Her company is developing a new tablet form obesity drug
Obesity and diabetes are the primary targets of a new tablet treatment under development by Malmö-based Pila Pharma. The company’s ambition is to take on the bi...
-
Don't miss ZEISS Quality Innovation Days
Digital event April 15-19, 2024.
-
In search of Marcel Proust's lost health
A great writer, but also a weak person and a hypochondriac. That has been the usual image of Marcel Proust. But the pediatrician and literary scholar Carl Lindg...
-
Advancing 3D Culture Imaging: Insights from Academia, Biotech, and Pharma
Webinar | March 13, 2024, 12 PM EST.
-
List: The coolest names in biotech
Hairy beasts, volcanic material and space strolling stand out on a US list of the best biotech company names, and on a list of the coolest names for pharmaceuti...
-
Stockholm and Uppsala jointly form a life science cluster
Stockholm and Uppsala are strengthening cooperation in medical research and biotech.
-
This years Nobel prize in medicine – “Changed the understanding of how genes are controlled”
This year’s Nobel Prize in Physiology or Medicine goes to the discovery that small RNA molecules, known as microRNAs, control how genes are regulated. Understan...
-
Glatt besked för Lundabolag – Europapatent på väg att beviljas
Synact Pharma kommer att beviljas europeiskt patent för den kliniska formuleringen av Resomelagon, enligt ett förhandsbesked till företaget.
-
Vd-skifte på Hamlet Biopharma
Hamlet Biopharma utser tidigare styrelseordföranden Catharina Svanborg till ny vd. Hon ersätter Martin Erixon som lämnar bolaget med omedelbar verkan.
-
ZEISS Quality Innovation Days: April 15 – 19, 2024
Be there when industry experts give exciting insights into different applications and trends in 90 minutes on various theme days.
-
Anna Törner: The clinical trial – Periscope to reality
What happens to the patients in the clinical trial is not very interesting, writes Anna Törner in a column.
-
It couldn’t be simpler
AI-assisted ZEISS Solution inspects implant coatings automatically.
-
Digital Temperature Sensors from ZEISS
New Metrology Expert Tip video.
-
CROs in drug development: "We use our expertise to speed up the process
Consultancy firms have become an increasingly important part of drug development. “It’s a trend and a business model that works, and we see no indication that i...
-
Advancing Drug Discovery by Combining Complex In-Vitro Models with AI-Powered 3D/4D Image Analysis
Free webinar organized by ZEISS.
-
Astra Zeneca’s Sweden CEO: “We have great faith in our portfolio”
It all started with a summer job as an operator at Astra’s chemical factory in Snäckviken, just outside Södertälje. More than three decades and countless differ...
-
“Don’t postpone the transition to IVDR”
Operators who have not yet started to adapt to the requirements of the new EU IVDR regulation are running out of excuses. This is the opinion of Helena Dzojic, ...
-
The First Multi-Technology System from ZEISS
Microscope and measuring machine in one.
-
Total pipeline of pharmaceutical companies reaches a record high – 22,921 medicines are currently being developed
Despite the difficult economic times, pharmaceutical companies have never developed as many new drugs as now.
-
An easy way to handle microtiter plate stacks
Do you want to automate handling of microtiter plates.? Have a look at a very simple solution on how to handle them.
-
One last chance to register for the premier metrology event in 2024
ZEISS QUALITY INNOVATION SUMMIT.
-
Ingrid Lönnstedt: What does the p-value mean?
The smaller the better, and preferably smaller than 0.05. A p-value smaller than 5% means that the treatment effect is statistically significant at 5% significa...
-
Pneumatics Makes a Technological Leap with Piezo
The first high-precision proportional valve terminal VTEP opens up new application areas
-
To build trust, one must be able to say “I don’t know” – whether human or AI
Will AI strengthen or break down trust? It depends on whether we can understand and accept its limitations, and our own, writes Sarah Lidé in a column.